(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on advanced kidney cancer with a presentation by Dr. Ozcan Yildiz discussing new systemic therapies in advanced RCC. Dr. Yildiz started by highlighting that in 2000, the survival of metastatic RCC was quite poor, with a median OS of 5 months for those with poor-risk disease, 14 months for intermediate-risk disease, and 30 months for favorable-risk disease. Since then, there has been an explosion of FDA approvals for drugs in this disease space as highlighted in the following timeline: